Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Epidermal growth factor receptor (EGFR) is a cell surface molecule and member of the ErbB family of receptor tyrosine kinases. Its activation leads to proliferation, antiapoptosis, and metastatic spread, making inhibition of this pathway a compelling target. In recent years, an increasing number of clinical trials in the management of solid malignancies have become available indicating the clinical efficacy of anti-EGFR monoclonal antibodies and oral small molecule tyrosine kinase inhibitors (TKIs). This review addresses frequently used EGFR inhibitors, summarizes clinical efficacy data of these new therapeutic agents, and discusses their associated toxicity and management.

• Publication year

  2009

• Venue

  Journal of Oncology

• Publication date

  2009-05-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2009/567486PMID 19424511PMCID 2677718
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

  2023cited by this paper
• A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

  2013cited by this paper
• Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature

  2009cited by this paper
• EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

  2008cited by this paper
• Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

  2008cited by this paper
• KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008influential reference
• Final survival and safety results from a multicenter, open‐label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

  2008cited by this paper
• Phase II trial of sorafenib in advanced thyroid cancer.

  2008cited by this paper
• Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

  2008cited by this paper
• An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

  2008cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.

  2008cited by this paper
• Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.

  2008cited by this paper
• FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• SORAFENIB IN ADVANCED RENAL CELL CARCINOMA (RCC): SURVIVAL AND BIOMARKER RESULTS FROM A PHASE III TRIAL

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

  2008cited by this paper
• Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008influential reference
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008cited by this paper
• Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.

  2007cited by this paper
• Mechanisms for oncogenic activation of the epidermal growth factor receptor.

  2007influential reference
• Epidermal growth factor receptor mutations in lung cancer

  2007influential reference
• Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data

  2007cited by this paper
• Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

  2007cited by this paper
• Capecitabine Therapy of Central Nervous System Metastases from Breast Cancer

  2007cited by this paper
• Successful management of infusion reaction accompanying the start of cetuximab therapy

  2007cited by this paper
• Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study

  2007cited by this paper
• Computational identification of inhibitors of protein-protein interactions.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• FDA drug approval summary: panitumumab (Vectibix).

  2007cited by this paper
• EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)

  2007influential reference
• 3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Management and preparedness for infusion and hypersensitivity reactions.

  2007cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• Molecular design and clinical development of VEGFR kinase inhibitors.

  2007cited by this paper
• Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

  2007cited by this paper
• Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

  2007cited by this paper
• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP).

  2006cited by this paper
• Epidermal Growth Factor Receptor Expression in Pancreatic Carcinoma Using Tissue Microarray Technique

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• EGFR alterations in pancreatic ductal adenocarcinoma: a chromogenic in situ hybridization analysis based on tissue microarrays.

  2006influential reference
• EGF–ERBB signalling: towards the systems level

  2006cited by this paper
• Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• Sunitinib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR).

  2006cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Role of panitumumab in the management of metastatic colorectal cancer.

  2006cited by this paper
• Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)

  2006cited by this paper
• Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

  2005cited by this paper
• Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance in patients with inoperable stage III non-small cell lung cancer

  2005influential reference
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005influential reference
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005influential reference
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005influential reference
• Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

  2005cited by this paper
• Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004influential reference
• Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

  2004cited by this paper
• Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours

  2004cited by this paper
• Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?

  2004cited by this paper
• Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

  2004cited by this paper
• Cetuximab in the treatment of colorectal cancer.

  2004influential reference
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004influential reference
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.

  2003influential reference
• Epidermal Growth Factor as a Biologic Switch in Hair Growth Cycle*

  2003cited by this paper
• FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

  2003cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Targeting the epidermal growth factor receptor for cancer therapy.

  2002cited by this paper
• Chemoprevention of breast cancer: a model for change.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.

  2002cited by this paper
• Age, anemia, and fatigue.

  2002cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

  2001cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Epidermal growth factor inhibits Ca(2+)-dependent Cl- transport in T84 human colonic epithelial cells.

  1996cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure.

  1995cited by this paper
• Immunohistochemical expression of epidermal growth factor receptors in nuclei of a subpopulation of keratinocytes and sweat gland cells.

  1991cited by this paper
• Immunolocalization of epidermal growth factor receptors in normal developing human skin.

  1990cited by this paper
• Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition.

  1985cited by this paper

• B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities.

  2026cites this paper
• A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial

  2025cites this paper
• Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors

  2024cites this paper
• Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

  2024cites this paper
• Emerging Targeted Therapies in Oral Oncology: Focus on EGFR Inhibition

  2024cites this paper
• Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system

  2023cites this paper
• Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins

  2023cites this paper
• Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease

  2023cites this paper
• Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with α-Substituent Electrophiles Targeting Cysteine

  2023cites this paper
• Beyond HER2: Targeting the ErbB receptor family in breast cancer.

  2022cites this paper
• Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database

  2022cites this paper
• In silico design of EGFRL858R/T790M/C797S inhibitors via 3D-QSAR, molecular docking, ADMET properties and molecular dynamics simulations

  2022cites this paper
• Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma

  2022cites this paper
• Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists

  2022cites this paper
• Metabolomics of the secondary metabolites of Ammi visnaga L. roots (family Apiaceae) and evaluation of their biological potential

  2022cites this paper
• A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses

  2021cites this paper
• New Predictive Biomarkers for Ovarian Cancer

  2021cites this paper
• Toxicités des traitements systémiques dans le cancer bronchique

  2021cites this paper
• Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase® the WHO Global Database of Individual Case Safety Reports

  2021cites this paper
• The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities

  2021cites this paper
• Calcium-activated chloride channel is involved in the onset of diarrhea triggered by EGFR tyrosine kinase inhibitor treatment in rats.

  2021cites this paper
• Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers

  2021cites this paper
• The Use of Traditional Chinese Medicine in Relieving EGFR-TKI-Associated Diarrhea Based on Network Pharmacology and Data Mining

  2021cites this paper
• Chemotherapy-induced bowel ischemia: diagnostic imaging overview

  2021cites this paper
• Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”

  2020cites this paper
• Dermatological Toxicities of Targeted Therapy

  2020cites this paper
• Loss of p120ctn causes EGFR-targeted therapy resistance and failure

  2020cites this paper
• Gefitinib induced severe hyponatremia: A case report

  2020cites this paper
• Computational Studies of Potent Covalent Inhibitors on Wild Type or T790M/L858R Mutant Epidermal Growth Factor Receptor.

  2020cites this paper
• Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

  2020cites this paper
• Adverse events of targeted anticancer therapies: What radiologists need to know

  2020cites this paper
• Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models

  2020cites this paper
• Adverse events of targeted anticancer therapies: what radiologists need to know.

  2020cites this paper
• Anticancer activity evaluation of indazolyl-substituted piperidin-4-yl-aminopyrimidines

  2020cites this paper
• Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity

  2020cites this paper
• Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

  2019cites this paper
• Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling

  2019cites this paper
• Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study

  2019influential citation
• EGFR-TKI不良反应管理专家共识

  2019cites this paper
• STAT3 as a Major Contributor to Chemoresistance

  2019cites this paper
• Managing dermatologic changes of targeted cancer therapy.

  2019cites this paper
• Potential Successes and Challenges of Targeted Cancer Therapies.

  2019cites this paper
• Immunohistochemical localization of afatinib in male rat intestines and skin after its oral administration.

  2019cites this paper
• Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea

  2019cites this paper
• Stomatitis and EGFR-tyrosine kinase inhibitors: a review of current literature in 4353 patients

  2019cites this paper
• Novel treatment strategies for breast, lung and cervical cancer

  2019cites this paper
• Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

  2018cites this paper
• Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

  2018cites this paper
• Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats

  2018cites this paper
• Innovations in lung cancer treatment

  2018cites this paper
• Evaluation of pharmacokinetics and toxicology of biosimilar APZ001 antibody in Macaca cynomolgus

  2018cites this paper
• Mechanism of action of Tarloxotinib, a hypoxia-activated pan-HER inhibitor: Potential for targeting wild-type EGFR in non-small cell lung cancer

  2017cites this paper
• Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors

  2017cites this paper
• Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities.

  2017cites this paper
• Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation

  2017cites this paper
• Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis

  2017influential citation
• Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin Toxicities

  2017cites this paper
• ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR

  2017cites this paper
• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

  2017cites this paper
• Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.

  2016cites this paper
• A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

  2016cites this paper
• Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

  2016cites this paper
• Cutaneous toxic effects of targeted therapy: clinical manifestations and correction

  2016cites this paper
• The safety of afatinib for the treatment of non-small cell lung cancer

  2016cites this paper
• In vitro and in vivo models to assess the mechanism of lapatinib-induced diarrhoea

  2016cites this paper
• Multiplexed Analysis for Anti-Epidermal Growth Factor Receptor Tumor Cell Growth Inhibition Based on Quantum Dot Probes.

  2016cites this paper
• EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction

  2016cites this paper
• Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.

  2016cites this paper
• Management of egfr tki-induced dermatologic adverse events.

  2015cites this paper
• Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib

  2015cites this paper
• Lewisy Promotes Migration of Oral Cancer Cells by Glycosylation of Epidermal Growth Factor Receptor

  2015cites this paper
• Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

  2015influential citation
• Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non‐small‐cell lung cancer: A meta‐analysis of 15 phase II/III randomized trials

  2015cites this paper
• Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

  2015cites this paper
• Experience with erlotinib in the treatment of non-small cell lung cancer

  2015cites this paper
• in cells

  2014cites this paper
• Spectrum of digestive tract complications related to oncologic therapy

  2014cites this paper
• Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.

  2014cites this paper
• Abdominal and pelvic complications of nonoperative oncologic therapy.

  2014cites this paper
• Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs

  2014cites this paper
• Development of the Rat Model of Lapatinib-Induced Diarrhoea

  2014cites this paper
• [Continued on nextpage] (54) Title: COMBINATIONS OF A MEK INHIBITOR COMPOUND WITH AN HER3/EGFR INHIBITOR COMPOUND AND METHODS OF USE

  2014cites this paper
• Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy

  2014cites this paper
• Targeted therapy-induced diarrhea: A review of the literature.

  2014cites this paper
• Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis

  2014cites this paper
• Splenomegaly-Associated Thrombocytopenia After Hepatic Yttrium-90 Radioembolization

  2013cites this paper
• Organtoxizität medikamentöser Tumortherapien

  2013cites this paper
• Targeting tumors with nanobodies for cancer imaging and therapy.

  2013cites this paper
• Diarrhea associated with afatinib: an oral ErbB family

  2013cites this paper
• Routes of Delivery for Biological Drug Products

  2013cites this paper
• Original Paper Lip Squamous Carcinoma - Epidemiologic, Clinical, Evolutive and Therapeutical Aspects

  2013cites this paper
• Complications of oncologic therapy in the abdomen and pelvis: a review

  2013cites this paper
• A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer

  2013cites this paper
• Mechanisms of TKI-induced diarrhea in cancer patients

  2013cites this paper
• Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis

  2013cites this paper
• Rationale for the design of an oncology trial using a generic targeted therapy multi-drug regimen for NSCLC patients without treatment options (Review)

  2013influential citation
• Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.

  2013cites this paper
• Diarrhea associated with afatinib: an oral ErbB family blocker

  2013cites this paper
• A Deimmunized Bispecific Ligand-Directed Toxin That Shows an Impressive Anti–Pancreatic Cancer Effect in a Systemic Nude Mouse Orthotopic Model

  2012cites this paper
• Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.

  2012cites this paper